. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Expert Rev Mol Diagn. 2016 Dec;16(12):1337–1351. doi: 10.1080/14737159.2016.1259069

Table 2.

Clinical trials evaluating molecular therapeutics in ovarian cancer patients.

Actionable Target	Therapeutic	Response Rate	Reference	Ongoing Trials
RAS/RAF/MEK	Selumetinib	15%	[114]	NCT00551070
BRCA1/2	Olaparib	18–44%	[96, 97, 157–164]	NCT02571725 NCT02282020 NCT02476968 NCT02340611 NCT01623349 NCT02477644 NCT02484404 NCT02345265 NCT02446600 NCT02502266 NCT02121990 NCT02418624 NCT02485990
	Niraparib	40%	[165]	NCT02354131 NCT02655016 NCT02354586 NCT02657889
	Rucaparib	2%	[166]	NCT01482715
	Veliparib	0–35%	[99, 167–169]	NCT02470585 NCT01749397
EGFR	Gefitinib	4–90%	[170–173]	NCT00317772
	Erlotinib	6–23.1%	[174–179]
	Cetuximab	4%	[180, 181]
ER/PR	Anastrozole	9–22%	[115, 182]	NCT02476955 NCT02188550 NCT02584465 NCT02285179
	Tamoxifen
	Leuprolide acetate
HER2	Trastuzumab		[60]
	Pertuzumab	74%	[131]
	Lapatinib		[134, 183]	NCT02342587
PTEN/PI3K/AKT/mTOR	Perifosine	5%	[124]
	Temsirolimus	9%	[125]
	MKC-1		[184]
SRC	Dasatinib		[180, 185]	NCT02059265
SRC	Saracatinib	53%	[186, 187]
TP53	MK 1775		[188]	NCT02101775
VEGFR	Bevacizumab	15.9–78.5%	[189–196]	NCT02354131 NCT02393898 NCT01802749 NCT01735071 NCT02606305 NCT02659384 NCT02839707 NCT02641639
	Aflibercept	10–54%	[197, 198]
	Cediranib	26–44%	[161, 199–201]	NCT02340611 NCT02484404 NCT02345265 NCT02446600 NCT02502266
	Sorafenib	4.7–69%	[202–209]
	Sunitinib	3.3–16.7%	[210–212]	NCT00979992 NCT01824615
	Pazopanib	18%	[213–215]	NCT01238770 NCT01262014 NCT01402271 NCT01402271 NCT01600573 NCT01610206 NCT02055690 NCT02383251